Select Language
PCSK9
PCSK9 Overview
| English Name | Proprotein convertase subtilisin kexin type 9 | Approved Drugs | 8 |
| Drugs in Clinical Trials | 36 | Target Synonym | EC 3.4.21，Neural apoptosis-regulated convertase 1，Proprotein convertase 9，NARC1，PSEC0052，PCSK9，NARC-1，EC:3.4.21.-，Proprotein Convertase Subtilisin/Kexin Type 9，Subtilisin/Kexin-Like Protease PC9，PC9，Convertase Subtilisin/Kexin Type 9 Preproprotein，Hypercholesterolemia， Autosomal Dominant 3，EC 3.4.21.-，HCHOLA3，LDLCQ1，FH3，EC 3.4.21.111，Neural Apoptosis Regulated Convertase 1，FHCL3 |
| Highest Development Stage | Approved | ||
| English Name | Proprotein convertase subtilisin kexin type 9 |
| Target Synonym | EC 3.4.21，Neural apoptosis-regulated convertase 1，Proprotein convertase 9，NARC1，PSEC0052，PCSK9，NARC-1，EC:3.4.21.-，Proprotein Convertase Subtilisin/Kexin Type 9，Subtilisin/Kexin-Like Protease PC9，PC9，Convertase Subtilisin/Kexin Type 9 Preproprotein，Hypercholesterolemia， Autosomal Dominant 3，EC 3.4.21.-，HCHOLA3，LDLCQ1，FH3，EC 3.4.21.111，Neural Apoptosis Regulated Convertase 1，FHCL3 |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 36 |
| Highest Development Stage | Approved |
PCSK9 Product List
- Product Category
Protein (13)Kits (3)
- Product Status
Launched (15)In Research (1)
- Species
Human (9)Mouse (2)Rat (1)Rhesus macaque (1)Cynomolgus (2)Hamster (1)
- Tag
His Tag (8)His Tag & Avi Tag (4)Fc Tag (1)- (3)
- Conjugate
Unconjugated (9)Biotin-labeled (4)- (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT PC9-H5223 |  Human | HEK293 | Human PCSK9 Protein, His Tag, low endotoxin (MALS verified) |  |  |  |
HOT PC9-H5256 | Human | HEK293 | Human PCSK9 Protein, Fc Tag |  | | |
HOT PC9-H82E7 | Human | HEK293 | Biotinylated Human PCSK9 Protein, Avitag™,His Tag (MALS verified) |  | | |
HOT PCY-H5225 | Human | HEK293 | Human PCSK9 (D374Y) Protein, His Tag, low endotoxin (MALS verified) |  | | |
HOT PCY-H82E7 | Human | HEK293 | Biotinylated Human PCSK9 (D374Y) Protein, Avitag™,His Tag |  | | |
HOT PC9-C5223 |  Cynomolgus | HEK293 | Cynomolgus PCSK9 Protein, His Tag, low endotoxin |  | | |
CEA-C202 | Human | - | Human PCSK9 ELISA Kit | |||
EP-103 | Human | - | PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair | |||
FRT-P040 | Human | - | Human PCSK9 / LDL R Inhibitor Screening Kit (TR-FRET) | |||
PC9-H52H7 | Human | HEK293 | Human PCSK9 Protein, C-terminal domain truncated, His Tag, low endotoxin |  | |
Total: 16
- 1
- 2
PCSK9 Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is also known as NARC1 (neural apoptosis regulated convertase), is a newly identified subtilase belonging to the peptidase S8 subfamily. Mouse PCSK9 is synthesized as a soluble zymogen, and undergoes autocatalytic intramolecular processing in the endoplasmic reticulum, resulting in the cleavage of its propeptide that remains associated with the secreted active enzyme with a broad alkaline pH optimum. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
PCSK9 Synonyms
PCSK9,FH3,HCHOLA3,LDLCQ1,NARC1,PC9
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Recombinant human anti-PCSK9 monoclonal antibody (Salubris) | SAL003 | Phase 3 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
| SYH-2053 | SYH2053; SYH-2053 | Phase 3 Clinical | CSPC Pharmaceutical Group Ltd | Dyslipidemias; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Sitosterolemia | Details |
| RBD-7022 | RBD7022; RBD-7022; SR043; SR-043; QLC-7401 | Phase 3 Clinical | Suzhou Ribo Life Science Co Ltd | Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Sitosterolemia | Details |
| Laroprovstat | AZD-0780; AZD0780 | Phase 3 Clinical | Dogma Therapeutics | Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hepatic Insufficiency; Heterozygous familial hypercholesterolemia; Renal Insufficiency | Details |
| Enlicitide Decanoate | MK-0616 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Hepatic Insufficiency; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Kidney Diseases; Renal Insufficiency; Sitosterolemia | Details |
| AZD-8233 | AZD-8233; IONIS-AZ4-2.5-LRx; ION-449 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Dyslipidemias; Hypercholesterolemia; Hyperlipidemias; Kidney Failure, Chronic | Details |
| CVI-LM-001 | CVI-LM-001; CVI-LM001; C-8304 | Phase 2 Clinical | Xiwei'Ai Medicine Technology (Shanghai) Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| ATX-304 | O-304; ATX-304; O-304X | Phase 2 Clinical | Betagenon Ab | Diabetes Mellitus, Type 2; Mitochondrial Diseases; Peripheral Arterial Disease | Details |
| MIL-86 | MIL-86 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Cardiovascular Diseases; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| NNC0385-0434 | NNC0385-0434; NN-6435; NNC 0385 0434 | Phase 2 Clinical | Novo Nordisk A/S | Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypercholesterolemia; Renal Insufficiency, Chronic | Details |
| ARO-DIMER-PA | ARO-DIMER-PA | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
| BEBT-701 | BEBT-701 | Phase 2 Clinical | Guangzhou BeBetter Medicine Technology Co | Hypercholesterolemia; Hyperlipidemias; Hypertension | Details |
| DNV-001 | DNV-001; DNV001 | Phase 2 Clinical | Hangzhou Dingle New Biotechnology Co Ltd | Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined | Details |
| YKYY-015 | YKYY015; YKYY-015 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd | Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias | Details |
| PCSK9 Inhibitors therapy(Guangdong Provincial People'S Hospital) | Phase 2 Clinical | Guangdong Provincial People'S Hospital | Colorectal Neoplasms | Details | |
| Recombinant human anti-PCSK9 monoclonal antibody (Tasly Pharm) | B1655; B-1655 | Phase 1 Clinical | Tianjin Tasly Pharmaceutical Co Ltd | Hypercholesterolemia | Details |
| DC-371739 | JYP-0739; DC-371739 | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Dyslipidemias; Hypercholesterolemia; Hyperlipidemias | Details |
| Anti-PCSK9 monoclonal antibody (Biocad) | Phase 1 Clinical | BIOCAD JSC | Cardiovascular Diseases | Details | |
| ATH-04 | ATH-04; Affitope AT04A | Phase 1 Clinical | Affiris Ag | Atherosclerosis | Details |
| VERVE-101 | VERVE-101 | Phase 1 Clinical | Broad Institute, Harvard University | Atherosclerosis; Cardiovascular Diseases; Heterozygous familial hypercholesterolemia; Hypercholesterolemia | Details |
| ART-002g1 | ART002g1; ART-002g1 | Phase 1 Clinical | Shanghai Jiao Tong University Affiliated First People'S Hospital | Heterozygous familial hypercholesterolemia | Details |
| RN-5681 | RN-5681; RN5681 | Phase 1 Clinical | Rona Therapeutics Inc | Atherosclerosis; Hypercholesterolemia | Details |
| PRD-001 | PRD001; PRD-001 | Phase 1 Clinical | PRD Therapeutics Inc | Fatty Liver; Homozygous familial hypercholesterolemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| ZRC-3306 | ZRC-3306 | Phase 1 Clinical | Zydus Lifesciences Ltd | Dyslipidemias | Details |
| STX-1150 | STX1150; STX-1150 | Phase 1 Clinical | Scribe Therapeutics Inc | Cardiovascular Diseases; Hypercholesterolemia | Details |
| SAL-092 | SAL092; SAL-092 | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Dyslipidemias; Hypercholesterolemia | Details |
| VERVE-102 | VERVE-102 | Phase 1 Clinical | Verve Therapeutics Inc | Atherosclerosis; Coronary Disease; Heterozygous familial hypercholesterolemia | Details |
| SRSD-101 | SRSD101; SRSD-101; SRS001; SRS-001 | Phase 1 Clinical | Sirius Therapeutics Inc | Cardiovascular Diseases; Hypercholesterolemia | Details |
| SGB-3403 | SGB-3403 | Phase 1 Clinical | Suzhou Sanegene Bio Inc | Atherosclerosis; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias | Details |
| RN-0191 | RN0191 | Phase 1 Clinical | Darui Biomedical Technology (Shanghai) Co Ltd | Atherosclerosis; Dyslipidemias; Hypercholesterolemia | Details |
| RP-910 | RP910; RP-910 | Phase 1 Clinical | Risen(Shanghai) Pharma Tech Co Ltd | Hyperlipidemias; Metabolic Diseases | Details |
| SAL-061 | YOLT-101; SAL-061; SAL061 | Phase 1 Clinical | Shanghai Yaotang Biotechnology Co Ltd | Heterozygous familial hypercholesterolemia; Hyperlipoproteinemia Type II | Details |
| JX-7002 | JX7002; JX-7002 | Phase 1 Clinical | Zhejiang Jingxin Pharmaceutical Co Ltd | Hypercholesterolemia; Hyperlipidemias | Details |
| NN-6434 | NN-6434 | Phase 1 Clinical | Novo Nordisk A/S | Details | |
| PCSK9 modulator (Genekey Biotech) | Phase 1 Clinical | Shenzhen Salubris Pharmaceuticals Co Ltd | Inflammation; Metabolic Diseases | Details | |
| ART-002(Ruizheng Gene) | ART002; ART-002; ART-002(Ruizheng Gene) | Clinical | Ruizheng Gene (Suzhou) Co Ltd | Heterozygous familial hypercholesterolemia | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Inclisiran sodium | ALN-60212; PCSK9si; ALN-PCSsc; KJX839; KJX-839 | Approved | Alnylam Pharmaceuticals Inc | Leqvio, 乐可为 | EU | Dyslipidemias; Hypercholesterolemia | Novartis Europharm Ltd | 2020-12-09 | Acute Coronary Syndrome; Atherosclerosis; Cardiovascular Diseases; Carotid Artery Diseases; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipoproteinemias; Myocardial Infarction; Renal Insufficiency; Stroke | Details |
| Ongericimab | JS-002 | Approved | Shanghai Junshi Biosciences Co Ltd | 君适达 | Mainland China | Hypercholesterolemia; Dyslipidemias | Shanghai Junshi Biosciences Co Ltd | 2024-10-09 | Atherosclerosis; Dyslipidemias; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia; Neoplasms | Details |
| Lerodalcibep | LIB-003; HST 101 | Approved | Lib Therapeutics Llc | United States | Hypercholesterolemia | LIB Therapeutics Inc | 2025-12-12 | Arteriosclerosis; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Metabolic Diseases; Stroke | Details | |
| Ebronucimab | AK-102 | Approved | Yabao Us Pharmaceutical Co Ltd | 伊喜宁 | Mainland China | Hypercholesterolemia; Dyslipidemias | Kang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd | 2024-09-26 | Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II | Details |
| Recaticimab | SHR-1209 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾心安 | Mainland China | Hypercholesterolemia; Dyslipidemias | Guangdong Hengrui Pharmaceutical Co Ltd | 2025-01-08 | Dyslipidemias; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II; Intracranial Arteriosclerosis | Details |
| Evolocumab | AMG-145 | Approved | Amgen Inc, Astellas Pharma Inc | 瑞百安, Repatha | EU | Dyslipidemias; Hypercholesterolemia | Amgen Europe Bv | 2015-07-17 | Acute Coronary Syndrome; Aortic Aneurysm, Abdominal; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dyslipidemias; Glioblastoma; Glioma; Heart Failure, Systolic; Heterozygous familial hypercholesterolemia; HIV Infections; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Myocardial Infarction; Rejection in heart transplantation; Sepsis; ST Elevation Myocardial Infarction; Stroke | Details |
| Tafolecimab | IBI-306 | Approved | 信必乐 | Mainland China | Dyslipidemias; Hypercholesterolemia | Innovent Biologics(Suzhou) Co Ltd | 2023-08-15 | Aortic Valve Stenosis; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias | Details | |
| Alirocumab | 316P; REGN-727; SAR-236553 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | 波立达, Praluent | United States | Hypercholesterolemia | Regeneron Pharmaceuticals Inc | 2015-07-24 | Acute Coronary Syndrome; Angina Pectoris; Atherosclerosis; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Drinking Behavior; Dyslipidemias; Hemorrhage; Heterozygous familial hypercholesterolemia; HIV Infections; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Intracranial Arteriosclerosis; Ischemic Stroke; Liver Diseases, Alcoholic; Myocardial Infarction; Plaque, Atherosclerotic; Sepsis; Shock, Septic; ST Elevation Myocardial Infarction; Stroke; Vascular Diseases | Details |
Product Reviews
1***02019-10-11
0People LikeExperiment purpose: antibody screening. Experiment method: Elisa. User experience: I purchased both small and big packages. It is stable from batch to batch and has excellent bioactivity. The experiment results are also very satisfying.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to: